Lidorestat
Alternative Names: EML 676; IDD 676; lindolrestat; lindorestatLatest Information Update: 04 Nov 2017
At a glance
- Originator Institute for Diabetes Discovery LLC
- Class Antihyperglycaemics; Indoleacetic acids; Small molecules; Thiazoles
- Mechanism of Action Aldehyde reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic neuropathies
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-neuropathies in North America (PO)
- 28 Sep 2005 A preclinical study has been added to the pharmacokinetics and Diabetes pharmacodynamics sections
- 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop lidorestat for diabetic complications